Use of the Kleihauer test to detect fetal erythroblasts in the maternal circulation.
Non-invasive prenatal diagnosis of aneuploidies on fetal nucleated erythrocytes present in the maternal circulation is hampered by the extremely small cell number of uncertain origin (70% of erythroblasts circulating during pregnancy have a maternal origin). Therefore, a method allowing selection of the fetal cells among the maternal cells is indispensable after the erythroblast enrichment step. In the present study, after an erythroblast enrichment step on a ficoll gradient followed by a positive immuno-magnetic selection with anti-CD71 or anti-GPA antibodies, a rapid, simple and direct chemical staining method adapted from the classical Kleihauer test was developed to select fetal cells. Precise differentiation between fetal and maternal erythroblasts is based on the constitutional difference between fetal and adult haemoglobin (Hb). The fetal cells appear with an intense pink cytoplasmic staining while maternal cells with adult haemoglobin are colourless. Preservation of the cytoplasmic integrity allows one to distinguish morphological characteristics and to visualize simultaneously nuclear hybridization signal by FISH (fluorescent in situ hybridization). This approach was tested by FISH analysis using dual-colour X- and Y-specific DNA probes on blood samples from 15 pregnant women, with the results being compared to cytogenetic or sonographic sex determination. For 12 pregnancies fetal sex was determined successfully (5 XY/7 XX), in two cases in situ hybridization failed, and in one case no fetal erythroblast was observed after the Kleihauer test. The selection method was applied to a pregnancy at risk for cystic fibrosis (CF). After a Kleihauer test, fetal erythroblasts were collected by microdissection, whole genomic DNA was amplified by primer extension pre-amplification (PEP) followed by a nested CF PCR. The fetal genotype was successfully characterized and confirmed by conventional prenatal diagnosis.
Laboratoire de Génétique Médicale, CHU Nancy, France.
V
V
Martel-Petit
C
C
Petit
M
M
Marchand
A
A
Fleurentin
B
B
Fontaine
A
A
Miton
P
P
Lemarie
C
C
Philippe
P
P
Jonveaux
D000906:Antibodies; D015703:Antigens, CD / Q000276:immunology; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology; D002467:Cell Nucleus / Q000648:ultrastructure; D004396:Coloring Agents; D003550:Cystic Fibrosis / Q000097:blood / Q000175:diagnosis / Q000235:genetics; D003593:Cytoplasm / Q000737:chemistry; D004900:Erythroblasts / Q000737:chemistry / Q000648:ultrastructure; D005260:Female; D005312:Fetal Blood / Q000166:cytology*; D005319:Fetal Hemoglobin / Q000032:analysis; D005838:Genotype; D005865:Gestational Age; D006021:Glycophorins / Q000276:immunology; D006801:Humans; D018189:Immunomagnetic Separation; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D011990:Receptors, Transferrin
D000906:Antibodies; D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; C068126:CD71 antigen; D004396:Coloring Agents; D006021:Glycophorins; D011990:Receptors, Transferrin; D005319:Fetal Hemoglobin